• Genomics & Informatics
• /
• 제12권4호
• /
• pp.247-253
• /
• 2014

Osteosarcoma is the most common primary bone tumor, generally affecting young people. While the etiology of osteosarcoma has been largely unknown, recent studies have suggested that cyclooxygenase-2 (COX-2) plays a critical role in the proliferation, migration, and invasion of osteosarcoma cells. To understand the mechanism of action of COX-2 in the pathogenesis of osteosarcoma, we compared gene expression patterns between three stable COX-2-overexpressing cell lines and three control cell lines derived from U2OS human osteosarcoma cells. The data showed that 56 genes were upregulated, whereas 20 genes were downregulated, in COX-2-overexpressed cell lines, with an average fold-change > 1.5. Among the upregulated genes, COL1A1, COL5A2, FBN1, HOXD10, RUNX2, and TRAPPC2 are involved in bone and skeletal system development, while DDR2, RAC2, RUNX2, and TSPAN31 are involved in the positive regulation of cell proliferation. Among the downregulated genes, HIST1H1D, HIST1H2AI, HIST1H3H, and HIST1H4C are involved in nucleosome assembly and DNA packaging. These results may provide useful information to elucidate the molecular mechanism of the COX-2-mediated malignant phenotype in osteosarcoma.

• Journal of Chest Surgery
• /
• 제31권12호
• /
• pp.1134-1146
• /
• 1998

배경:종양억제 유전자인 p53은 폐암을 비롯하여 인체에 발생될 수 있는 다양한 종양들에 있어서 가장 빈번히 변이를 일으키는 유전자로 알려져 왔으며, 정상적인 p53은 세포분화 과정 중 G1 arrest 또는 세포자멸을 통하여 세포 성장을 억제한다는 증거들이 발견되고있다. 더불어 유전자 치료에 p53을 사용할 수 있는지에 대해서도 많은 연구가 진행 중이다 대상 및 방법: 이런 p53 단백질의 기능을 이해하기 위한 한 가지 방법으로 정상세포나 종양세포 안에 과량의 p53을 발현시킬 수 있는 p53 표현 중개물(expression vectors)을 이용할 수 있다. 우리는 각기 다른 p53 성질을 지니고 있는 네가지 비소세포폐암 세포를 대상으로 정상적인 p53을 지닌 adenovirus를 이용하여 비소세포폐암에 Adenovirus-p53을 이입시킬 경우 p53 단백질이 증가하는지의 여부와 Adenovirus-p53이 종양세포의 성장에 미치는 영향을 관찰하였으며, p53에 의한 세포 독성에 있어서 세포자멸과의 관련성 여부 및 실험관 안에서 Adenovirus-p53이 비소세포폐암의 종양형성 능력에 미치는 영향을 관찰하였다. 결과: 이번 실험 결과는 다음과 같이 요약될 수 있다. 변이성 p53을 갖고 있거나 p53 유전자가 없는 비소세포폐암 세포는 정상적인 p53을 가지고 있는 종양세포에 비하여 Adenovirus-p53에 의한 세포성장 억제정도가 높았으며, p53을 과발현시킬 경우 세포자멸을 관찰할 수 있었다. 그리고 Adenovirus-p53은 비소세포폐암의 집락 형성 능력을 억제할 수 있고, 또 이미 형성된 집락도 그 성장을 억제할 수 있다는 사실도 확인하였다. 결과: 이번 실험의 결과로 adenovirus는 비소세포폐암 세포에 종양억제유전자를 이입시키는데 매우 효과적인 매개물이며, 특히 p53이 소실되거나, 변이를 일으킨 종양세포들은 Adenovirus-p53에 의하여 쉽게 세포자멸이 유발된다는 사실을 알게 되었다.

• 약학회지
• /
• 제38권1호
• /
• pp.31-37
• /
• 1994

Active fraction, $P_2$, was Isolated from natural anti-cancer drug, $CP_2$, by HPLC. We confirmed that $P_2$ includes most of the Isoguanosine and minor components, Berberine and other protoberberine alkaloids, by $^1H-NMR$ and $^{13}C-NMR$ and measured tile cytotoxicity of $P_2$ against various tumor cell-lines.' $P_2$ was very effective to all tumor cell-lines, especially to human colon cancer SNU-C2A$(ED_{50};\;24{\mu}g)$ and liver cancer HEP-3B$(ED_{50};\;27{\mu}g)$.

• 대한약학회:학술대회논문집
• /
• 대한약학회 2002년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2
• /
• pp.340.3-341
• /
• 2002

During the research for the development of antitumor agents. we found the 3-arylisoquinoline derivatives exhibited potent cytotoxicity against human tumor cell lines. For extending our study on these compounds. indeno［1.2-c］isoquinolines were chosen as the next research target due to previous studied data of the compounds that showed potent topoisomerase I inhibition activity as well as cytotoxicity against many kinds of tumor cell lines. Retrosynthetic consideration of indeno[1.2-d]isoquinolines indicates that the coupling of o-methyltoluamide with o-hydroxymethylbenxonitrile might afford 3-arylisoquinoline which could be translerred to the aldehtde. Indeno [1.2-c]isoquinolines can be formed by and inframolecular ring cyclization method. Various derlvatives of this compound including 11-alkoxy-6-methyl-6H. 11H-indeno[1.2-c]isoquinolin-5-one and biological activity will be presented with the docking model with topisomerase 1 enzyme.

• 한방안이비인후피부과학회지
• /
• 제13권1호
• /
• pp.129-140
• /
• 2000

ShingongNaetakSan(SNS) was drugs used in treatment of carbuncle and cellulitis in Oriental So, the purpose of this Study was to investigate effect of SNS on the proliferation of immunocytes and anti-cancer. This Study estimated the proliferation of L1210 cell lines and S-180 cell lines in vitro. and estimated the proliferation of L1210 cells, thymocytes and splenocytes, and tumor weight, body weight and mean survival rates in vivo. The proliferation and cytotoxicity of cells was tested using a colorimetric tetrazoliun assy(MTT assy). The results of this study were obtained as follow ; SNS had effect on the proliferation of L1210 cells in vitro and splenocytes in vivo, and SNS decreased significantly tumor weight, and increased significantly mean survival rates.

• 동의생리병리학회지
• /
• 제19권2호
• /
• pp.520-523
• /
• 2005

(R)-(-)-PGME amide of diterpene acid (2) was assigned the absolute configuration from NMR correlation experiments. The compound (2) was tested for its growth inhibitory effects against tumor cell lines by the MTT method.

• 한방안이비인후피부과학회지
• /
• 제15권2호
• /
• pp.132-144
• /
• 2002

Shinsuwuisaeng-Tang was a drug that treated carbuncle and cellulitis. So, the purpose of this Study was to investigate effect of Shinsuwuisaeng-Tang on the anti-cancer and nitric oxide(NO) production of peritoneal macrophages. We used Shinsuwuisaeng-Tang extract(SWT) with freeze-dried, 8wks-old male mice. and cancer cell lines(L1210, sarcoma-180) for this Study. The proliferation of cells was tested using a colorimetric tetrazoliun assay(MTT assay). The results of this Study were obtained as follow; SWT was showed cytotoxicity on the L1210 and sacoma-180(S-180) cell lines, SWT inhibited significantly proliferation of L1210 cells in L1210 cells transplanted mice, SWT accelerated NO production of peritoneal macrophages in L1210 cells transplanted mice. And SWT inhibited significantly tumor weight, increased significantly body weight and mean survival days in S-180 cells transplanted mice. This results suggest that SWT has anti-cancer by producing NO of peritoneal macrophages.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권5호
• /
• pp.2355-2362
• /
• 2012

The SH2B1 adaptor protein is recruited to multiple ligand-activated receptor tyrosine kinases that play important role in the physiologic and pathologic features of many cancers. The purpose of this study was to assess SH2B1 expression and to explore its contribution to the non-small cell lung cancer (NSCLC). Methods: SH2B1 expression in 114 primary NSCLC tissue specimens was analyzed by immunohistochemistry and correlated with clinicopathological parameters and patients' outcome. Additionally, 15 paired NSCLC background tissues, 5 NSCLC cell lines and a normal HBE cell line were evaluated for SH2B1 expression by RT-PCR and immunoblotting, immunofluorescence being applied for the cell lines. Results: SH2B1 was found to be overexpressed in NSCLC tissues and NSCLC cell lines. More importantly, high SH2B1 expression was significantly associated with tumor grade, tumor size, clinical stage, lymph node metastasis, and recurrence respectively. Survival analysis demonstrated that patients with high SH2B1 expression had both poorer disease-free survival and overall survival than other patients. Multivariate Cox regression analysis revealed that SH2B1 overexpression was an independent prognostic factor for patients with NSCLC. Conclusions: Our findings suggest that the SH2B1 protein may contribute to the malignant progression of NSCLC and could offer a novel prognostic indicator for patients with NSCLC.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권8호
• /
• pp.3659-3665
• /
• 2014

To assess inhibition mechanisms of a Phellinus igniarius (PI) extract on cancer, C57BL/6 mice were orally treated with PI extractive after or before implanting H22 (hepatocellular carcinoma ) or B16 (melanoma) cells. Mice were orally gavaged with different doses of PI for 36 days 24h after introduction of H22 or B16 cells. Mice in another group were orally treated as above daily for 42 days and implanted with H22 cells on day 7. Then the T lymphocyte, antibody, cytokine, LAK, NK cell activity in spleen, tumor cell apoptosis status and tumor inhibition in related organs, as well as the expression of iNOS and PCNA in tumor tissue were examined. The PI extract could improve animal immunity as well as inhibit cancer cell growth and metastasis with a dose-response relationship. Notably, PI's regulation with the two kinds of tumor appeared to occur in different ways, since the antibody profile and tumor metastasis demonstrated variation between animals implanted with hepatocellular carcinoma and melanoma cells.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권12호
• /
• pp.4937-4944
• /
• 2015

MicroRNAs (miRNAs) are emerging as critical regulators in carcinogenesis and tumor progression. Recently, miR-99a has been reported as a tumor suppressor gene in various human cancers, but its functions in the context of anaplastic thyroid cancer (ATC) remain unknown. In this study, we reported that miR-99a was commonly downregulated in ATC tissue specimens and cell lines with important functional consequences. Overexpression of miR-99a not only dramatically reduced ATC cell viability by inducing cell apoptosis and accumulation of cells at G1 phase, but also inhibited tumorigenicity in vivo. We then screened and identified a novel miR-99a target, mammalian target of rapamycin (mTOR), and it was further confirmed by luciferase assay. Up-regulation of miR-99a would markedly reduce the expression of mTOR and its downstream phosphorylated proteins (p-4E-BP1 and p-S6K1). Similar to restoring miR-99a expression, mTOR down-regulation suppressed cell viability and increased cell apoptosis, whereas restoration of mTOR expression significantly reversed the miR-99a antitumor activity and the inhibition of mTOR/p-4E-BP1/p-S6K1 signal pathway profile. In clinical specimens and cell lines, mTOR was commonly overexpressed and its protein levels were statistically inversely correlated with miR-99a expression. Taken together, our results demonstrated for the first time that miR-99a functions as a tumor suppressor and plays an important role in inhibiting the tumorigenesis through targeting the mTOR/p-4E-BP1/p-S6K1 pathway in ATC cells. Given these, miR-99a may serve as a novel prognostic/diagnostic and therapeutic target for treating ATC.